Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. cut its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 3.7% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 367,406 shares of the specialty pharmaceutical company’s stock after selling 14,088 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Collegium Pharmaceutical were worth $10,526,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Versor Investments LP boosted its holdings in Collegium Pharmaceutical by 36.2% in the fourth quarter. Versor Investments LP now owns 19,582 shares of the specialty pharmaceutical company’s stock valued at $561,000 after purchasing an additional 5,200 shares in the last quarter. Sanctuary Advisors LLC boosted its holdings in Collegium Pharmaceutical by 5.3% in the fourth quarter. Sanctuary Advisors LLC now owns 18,928 shares of the specialty pharmaceutical company’s stock valued at $542,000 after purchasing an additional 952 shares in the last quarter. Rhumbline Advisers boosted its holdings in Collegium Pharmaceutical by 5.8% in the fourth quarter. Rhumbline Advisers now owns 108,228 shares of the specialty pharmaceutical company’s stock valued at $3,101,000 after purchasing an additional 5,920 shares in the last quarter. Meritage Portfolio Management boosted its holdings in Collegium Pharmaceutical by 5.0% in the fourth quarter. Meritage Portfolio Management now owns 20,755 shares of the specialty pharmaceutical company’s stock valued at $595,000 after purchasing an additional 979 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Collegium Pharmaceutical by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock valued at $196,000 after purchasing an additional 642 shares in the last quarter.

Insider Activity

In related news, CFO Colleen Tupper sold 10,445 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total transaction of $313,454.45. Following the sale, the chief financial officer now directly owns 165,246 shares in the company, valued at approximately $4,959,032.46. This trade represents a 5.95 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Shirley R. Kuhlmann sold 27,500 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $33.04, for a total value of $908,600.00. Following the sale, the executive vice president now owns 119,184 shares in the company, valued at $3,937,839.36. This represents a 18.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 109,193 shares of company stock worth $3,243,594 over the last 90 days. 3.98% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on COLL. Piper Sandler lowered their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Finally, Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Collegium Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.60.

Collegium Pharmaceutical Price Performance

COLL stock opened at $30.05 on Friday. Collegium Pharmaceutical, Inc. has a twelve month low of $27.28 and a twelve month high of $42.29. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The business has a 50 day simple moving average of $30.69 and a 200-day simple moving average of $32.67. The company has a market capitalization of $946.15 million, a P/E ratio of 12.95 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. As a group, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.